Search: onr:"swepub:oai:lup.lub.lu.se:72212034-f1aa-4c6e-ac6c-b72b95c4b606" >
Less small-bowel in...
Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole
-
Hawkey, Christopher J (author)
-
Ell, Christian (author)
-
Simon, Bernd (author)
-
show more...
-
Albert, Joerg (author)
-
Keuchel, Martin (author)
-
Mcalindon, Mark (author)
-
Fortun, Paul (author)
-
Schumann, Stefan (author)
-
Bolten, Wolfgang (author)
-
Shonde, Anthony (author)
-
Hugot, Jean-Louis (author)
-
Yu, Vincent (author)
-
Arulmani, Udayasankar (author)
-
Krammer, Gerhard (author)
-
Rebuli, Rosemary (author)
-
- Toth, Ervin (author)
- Lund University,Lunds universitet,Institutionen för kliniska vetenskaper, Malmö,Medicinska fakulteten,Department of Clinical Sciences, Malmö,Faculty of Medicine
-
show less...
-
(creator_code:org_t)
- Elsevier BV, 2008
- 2008
- English.
-
In: Clinical Gastroenterology and Hepatology. - : Elsevier BV. - 1542-7714 .- 1542-3565. ; 6:5, s. 536-544
- Related links:
-
http://www.ncbi.nlm....
-
show more...
-
http://www.sciencedi...
-
http://dx.doi.org/10...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Background & Aims: The selective cyclooxygenase-2 inhibitor lumiracoxib has been shown to reduce endoscopically detected ulcers and ulcer complications in the upper gastrointestinal tract compared with nonselective nonsteroidal anti-inflammatory drugs. We investigated whether lumiracoxib would reduce small-bowel injury compared with naproxen plus omeprazole. Methods: Healthy volunteers were randomized to receive lumiracoxib, 100 mg once daily, naproxen 500 mg twice daily plus omeprazole 20 mg once daily, or placebo in a 16-day double-blind, parallel-group study. Small-bowel mucosal injury and inflammation were assessed by video capsule endoscopy, the lactulose:L-rhamnose permeability assessment, and the fecal calprotectin test. Results: Of 152 randomized subjects, 139 completed the study with valid video capsule endoscopies (lumiracoxib, n = 47; naproxen plus omeprazole, n = 45; placebo, n = 47). Compared with placebo, an increased number of subjects on naproxen plus omeprazole had small-bowel mucosal breaks (77.8% vs 40.4%, P < .001), with increased permeability (P = .023) and increased fecal calprotectin (increase, 96.8 vs 14.5 mg/kg for placebo; P < .001). With lumiracoxib, 27.7% of subjects had small-bowel mucosal breaks (P = .196 vs placebo; P < .001 vs naproxen), there was no increase in permeability (P = .157 vs placebo; P = .364 vs naproxen), and no increase in fecal calprotectin (-5.7 mg/kg; P = .377 vs placebo; P < .001 vs naproxen). Conclusions: As assessed by 3 different measures, acute small-bowel injury on lumiracoxib treatment is less frequent than with naproxen plus omeprazole and similar to placebo.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Gastroenterologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Gastroenterology and Hepatology (hsv//eng)
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
To the university's database
- By the author/editor
-
Hawkey, Christop ...
-
Ell, Christian
-
Simon, Bernd
-
Albert, Joerg
-
Keuchel, Martin
-
Mcalindon, Mark
-
show more...
-
Fortun, Paul
-
Schumann, Stefan
-
Bolten, Wolfgang
-
Shonde, Anthony
-
Hugot, Jean-Loui ...
-
Yu, Vincent
-
Arulmani, Udayas ...
-
Krammer, Gerhard
-
Rebuli, Rosemary
-
Toth, Ervin
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Gastroenterology ...
- Articles in the publication
-
Clinical Gastroe ...
- By the university
-
Lund University